Acetylsalicylic acid as an adjuvant therapy for schizophrenia

Completed

• Conditions: Schizophrenia, schizo-affective disorder, schizofreniform disorder; Mental and Behavioural Disorders; Schizophrenia

• Registration Number: ISRCTN27745631
• Lead Sponsor: niversity Medical Centre Utrecht (UMCU) (Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-05-16
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Schizophrenia, schizo-affective disorder, schizofreniform disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (for a maximum of 5 years) (as of 03/06/2008 this has been updated to a maximum of 10 years)
2. Aged 18 - 55 years
3. Stable
4. Minimum score of 60 on Positive and Negative Syndrome Scale (PANSS)
5. Minimum 2 x a score of minimum 4 on PANSS

Exclusion Criteria

1. No contra-indication for acetylsalicylic acid
2. No hypersensitivity to acetylsalicylic acid or pantoprazole
3. No significant somatic illness
4. No chronic use of a non-steroidal anti-inflammatory drug (NSAID)
5. No use of corticosteroids
6. Not pregnant
7. No drug dependency
8. Informed consent obtained

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Three-month change in positive and negative symptoms on the total PANSS score.

Secondary Outcome Measures

Name	Time	Method
1. Three-month change in the PANSS subscales<br>2. Cognitive symptoms<br>3. Immunological parameters (g-interferon, interleukin 4 [IL-4], interleukin 6 [IL-6] and interleukin 12 [IL-12])